| Dr Robert Andrew Headley, MD | |
|
2901 Brooks St, Missoula, MT 59801-7703 | |
| (406) 721-0918 | |
| Not Available |
| Full Name | Dr Robert Andrew Headley |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 23 Years |
| Location | 2901 Brooks St, Missoula, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790726198 | NPI | - | NPPES |
| 011001941 | Other | MT | MEDICARE ID- TYPE UNSPECIFIED |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 11641 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Patrick Hospital | Missoula, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Montana Clinic Pc | 2466365002 | 40 |
News Archive
People with a history of migraines and other headaches lasting at least four hours are more likely to report suffering from the chest pain doctors call angina than people who do not experience such headaches, a new University of North Carolina at Chapel Hill study concludes.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Unless new treatments are found, it is predicted that more than 100 million people worldwide will be affected by Alzheimer's disease by 2050. With very few new drugs in the pipeline, researchers are exploring every possible avenue to treat the disease.
Hearing loss, brittle bones, sagging skin, a deteriorating mind: these are just some of the issues associated with growing old.
A common genetic variation links to both bladder cancer risk and to the length of protective caps found on the ends of chromosomes, scientists at The University of Texas MD Anderson Cancer Center reported today at the AACR 102nd Annual Meeting.
› Verified 3 days ago
| Entity Name | Western Montana Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942253182 PECOS PAC ID: 2466365002 Enrollment ID: O20031110000361 |
News Archive
People with a history of migraines and other headaches lasting at least four hours are more likely to report suffering from the chest pain doctors call angina than people who do not experience such headaches, a new University of North Carolina at Chapel Hill study concludes.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Unless new treatments are found, it is predicted that more than 100 million people worldwide will be affected by Alzheimer's disease by 2050. With very few new drugs in the pipeline, researchers are exploring every possible avenue to treat the disease.
Hearing loss, brittle bones, sagging skin, a deteriorating mind: these are just some of the issues associated with growing old.
A common genetic variation links to both bladder cancer risk and to the length of protective caps found on the ends of chromosomes, scientists at The University of Texas MD Anderson Cancer Center reported today at the AACR 102nd Annual Meeting.
› Verified 3 days ago
| Entity Name | Lewis And Clark Emergency Physicians P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083668651 PECOS PAC ID: 0941196497 Enrollment ID: O20040223001126 |
News Archive
People with a history of migraines and other headaches lasting at least four hours are more likely to report suffering from the chest pain doctors call angina than people who do not experience such headaches, a new University of North Carolina at Chapel Hill study concludes.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Unless new treatments are found, it is predicted that more than 100 million people worldwide will be affected by Alzheimer's disease by 2050. With very few new drugs in the pipeline, researchers are exploring every possible avenue to treat the disease.
Hearing loss, brittle bones, sagging skin, a deteriorating mind: these are just some of the issues associated with growing old.
A common genetic variation links to both bladder cancer risk and to the length of protective caps found on the ends of chromosomes, scientists at The University of Texas MD Anderson Cancer Center reported today at the AACR 102nd Annual Meeting.
› Verified 3 days ago
| Entity Name | Clark Fork Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538384987 PECOS PAC ID: 1850491960 Enrollment ID: O20070702000592 |
News Archive
People with a history of migraines and other headaches lasting at least four hours are more likely to report suffering from the chest pain doctors call angina than people who do not experience such headaches, a new University of North Carolina at Chapel Hill study concludes.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Unless new treatments are found, it is predicted that more than 100 million people worldwide will be affected by Alzheimer's disease by 2050. With very few new drugs in the pipeline, researchers are exploring every possible avenue to treat the disease.
Hearing loss, brittle bones, sagging skin, a deteriorating mind: these are just some of the issues associated with growing old.
A common genetic variation links to both bladder cancer risk and to the length of protective caps found on the ends of chromosomes, scientists at The University of Texas MD Anderson Cancer Center reported today at the AACR 102nd Annual Meeting.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Andrew Headley, MD Po Box 7609, Missoula, MT 59807-7609 Ph: (406) 721-5600 | Dr Robert Andrew Headley, MD 2901 Brooks St, Missoula, MT 59801-7703 Ph: (406) 721-0918 |
News Archive
People with a history of migraines and other headaches lasting at least four hours are more likely to report suffering from the chest pain doctors call angina than people who do not experience such headaches, a new University of North Carolina at Chapel Hill study concludes.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Unless new treatments are found, it is predicted that more than 100 million people worldwide will be affected by Alzheimer's disease by 2050. With very few new drugs in the pipeline, researchers are exploring every possible avenue to treat the disease.
Hearing loss, brittle bones, sagging skin, a deteriorating mind: these are just some of the issues associated with growing old.
A common genetic variation links to both bladder cancer risk and to the length of protective caps found on the ends of chromosomes, scientists at The University of Texas MD Anderson Cancer Center reported today at the AACR 102nd Annual Meeting.
› Verified 3 days ago
Diana Griffith, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2827 Fort Missoula Rd, Missoula, MT 59804 Phone: 406-728-4100 | |
Dr. Amanda A Morey, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-329-5635 | |
Dr. Kevin Granger Eichhorn, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Saint Patrick Hospital Emergency Department, 500 West Broadway, Missoula, MT 59801 Phone: 406-329-5635 | |
Elizabeth J Grimley, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-721-5600 Fax: 406-721-3907 | |
David Westphal, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2827 Fort Missoula Rd, Missoula, MT 59804 Phone: 406-721-4800 | |
Dr. Douglas Carl Melzer, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 303-720-9622 | |
Dr. Robert C Mcdevitt, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-721-5600 Fax: 406-721-3907 |